Bone Research (Feb 2022)

Estrogen-mediated downregulation of HIF-1α signaling in B lymphocytes influences postmenopausal bone loss

  • Xianyi Meng,
  • Zhen Lin,
  • Shan Cao,
  • Iga Janowska,
  • Koshiro Sonomoto,
  • Darja Andreev,
  • Knab Katharina,
  • Jinming Wen,
  • Karl Xaver Knaup,
  • Michael Sean Wiesener,
  • Gerhard Krönke,
  • Marta Rizzi,
  • Georg Schett,
  • Aline Bozec

DOI
https://doi.org/10.1038/s41413-022-00189-x
Journal volume & issue
Vol. 10, no. 1
pp. 1 – 12

Abstract

Read online

Abstract In the bone marrow, B cells and bone-resorbing osteoclasts colocalize and form a specific microenvironment. How B cells functionally influence osteoclasts and bone architecture is poorly understood. Using genetically modified mice and high-throughput analyses, we demonstrate that prolonged HIF-1α signaling in B cells leads to enhanced RANKL production and osteoclast formation. In addition, deletion of HIF-1α in B cells prevents estrogen deficiency-induced bone loss in mice. Mechanistically, estrogen controls HIF-1α protein stabilization through HSP70-mediated degradation in bone marrow B cells. The stabilization of HIF-1α protein in HSP70-deficient bone marrow B cells promotes RANKL production and osteoclastogenesis. Induction of HSP70 expression by geranylgeranylacetone (GGA) administration alleviates ovariectomy-induced osteoporosis. Moreover, RANKL gene expression has a positive correlation with HIF1A expression in human B cells. In conclusion, HIF-1α signaling in B cells is crucial for the control of osteoclastogenesis, and the HSP70/HIF-1α axis may serve as a new therapeutic target for osteoporosis.